Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: The results will develop the genetic testing strategy in China

Breast Cancer Research and Treatment

Volumn 120, Issue 1, 2010, Pages 271-272

  Cao, A Yong ^a   Hu, Zhen ^a   Shao, Zhi Ming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DNA; PROTEIN P53;

BREAST CANCER; CANCER SUSCEPTIBILITY; CHINESE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA DAMAGE; ETHNIC GROUP; EXON; FAMILIAL CANCER; FAMILY HISTORY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HAPLOTYPE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LETTER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK REDUCTION; TUMOR GENE; WILD TYPE;

ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; RNA HELICASES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 74849109026     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0598-4     Document Type: Letter

References (10)

1. T Walsh MC King 2007 Ten genes for inherited breast cancer Cancer Cell 11 2 103 105 10.1016/j.ccr.2007.01.010 1:CAS:528:DC%2BD2sXitVartLw%3D 17292821 (Pubitemid 46209856)
2. WF Li Z Hu NY Rao, et al. 2008 The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified Breast Cancer Res Treat 110 99 109 10.1007/s10549-007-9708-3 1:CAS:528:DC%2BD1cXmslyjsrg%3D 17851763 (Pubitemid 351793864)
3. Cao AY, Jin W, Shi PC et al (2009) Identification and characterization of two novel germ line p53 mutations in the non-LFS/non-LFL breast cancer families in Chinese population. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0349-6
4. AY Cao J Huang Z Hu, et al. 2009 The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives Breast Cancer Res Treat 114 457 462 10.1007/s10549-008- 0036-z 1:CAS:528:DC%2BD1MXisFSqt7o%3D 18446436
5. AY Cao J Huang Z Hu, et al. 2009 Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives Breast Cancer Res Treat 115 51 55 10.1007/s10549-008-0052-z 1:CAS:528:DC%2BD1MXkvVyru7w%3D 18483852
6. CG Song Z Hu WT Yuan, et al. 2006 CHEK2 c. 1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23 443 445 1:CAS:528:DC%2BD2sXhtFejsr3K 16883537
7. SM Domchek BL Weber 2006 Clinical management of BRCA1 and BRCA2 mutation carriers Oncogene 25 5825 5831 10.1038/sj.onc.1209881 1:CAS:528: DC%2BD28XhtVSgurjK 16998496 (Pubitemid 44453437)
8. American Society of Clinical Oncology 2003 American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility J Clin Oncol 21 2397 2406 10.1200/JCO.2003.03.189 (Pubitemid 46908372)
9. SM Wang 2007 Concerns on diagnosis and treatment of breast cancer in China Chin Med J (Engl) 120 1741 1742
10. M Harris I Winship M Spriggs 2007 Controversies and ethical issues in cancer-genetics clinics Lancet Oncol 6 301 310 10.1016/S1470-2045(05)70166-2